CD28/B7 system of T cell costimulation.

T cells play a central role in the initiation and regulation of the immune response to antigen. Both the engagement of the TCR with MHC/Ag and a second signal are needed for the complete activation of the T cell. The CD28/B7 receptor/ligand system is one of the dominant costimulatory pathways. Interruption of this signaling pathway with CD28 antagonists not only results in the suppression of the immune response, but in some cases induces antigen-specific tolerance. However, the CD28/B7 system is increasingly complex due to the identification of multiple receptors and ligands with positive and negative signaling activities. This review summarizes the state of CD28/B7 immunobiology both in vitro and in vivo; summarizes the many experiments that have led to our current understanding of the participants in this complex receptor/ligand system; and illustrates the current models for CD28/B7-mediated T cell and B cell regulation. It is our hope and expectation that this review will provoke additional research that will unravel this important, yet complex, signaling pathway.

[1]  S. Korsmeyer,et al.  Apoptotic death of lymphocytes in murine acquired immunodeficiency syndrome: Involvement of Fas‐Fas ligand interaction , 1995, European journal of immunology.

[2]  R. Karr,et al.  Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4. , 1995, Journal of immunology.

[3]  J. Allison,et al.  CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation , 1995, The Journal of experimental medicine.

[4]  B Zheng,et al.  Cellular interaction in germinal centers. Roles of CD40 ligand and B7-2 in established germinal centers. , 1995, Journal of immunology.

[5]  C. Thompson,et al.  CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. , 1995, Immunity.

[6]  D. Loh,et al.  Naive CD28-deficient T cells can initiate but not sustain an in vitro antigen-specific immune response. , 1995, Journal of immunology.

[7]  R. Karr,et al.  Long-term inhibition of murine experimental autoimmune encephalomyelitis using CTLA-4-Fc supports a key role for CD28 costimulation. , 1995, The Journal of clinical investigation.

[8]  J. Gribben,et al.  B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. , 1995, Immunity.

[9]  G. Forni,et al.  Co‐expression of B7‐1 and ICAM‐1 on tumors is required for rejection and the establishment of a memory response , 1995, European journal of immunology.

[10]  P. Linsley,et al.  CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2 , 1995, The Journal of experimental medicine.

[11]  L. Chen,et al.  Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules. , 1995, Journal of immunology.

[12]  Laurie H Glimcher,et al.  B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: Application to autoimmune disease therapy , 1995, Cell.

[13]  J. Bluestone,et al.  Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse , 1995, The Journal of experimental medicine.

[14]  P. Albert,et al.  Role of B7:CD28/CTLA-4 in the induction of chronic relapsing experimental allergic encephalomyelitis. , 1995, Journal of immunology.

[15]  J. Ceuppens,et al.  FcR cross-linking on monocytes results in impaired T cell stimulatory capacity. , 1995, International immunology.

[16]  P. Linsley,et al.  Studies on the interdependence of gp39 and B7 expression and function during antigen‐specific immune responses , 1995, European journal of immunology.

[17]  C. June,et al.  CD28 activation promotes Th2 subset differentiation by human CD4+ cells , 1995, European journal of immunology.

[18]  J. Gribben,et al.  CTLA4 mediates antigen-specific apoptosis of human T cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[19]  H. Weiner,et al.  Reciprocal expression of co‐stimulatory molecules, B7‐1 and B7‐2, on murine T cells following activation , 1995, European journal of immunology.

[20]  P. Linsley,et al.  CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL. , 1995, Journal of immunology.

[21]  N. Perico,et al.  Toward novel antirejection strategies: in vivo immunosuppressive properties of CTLA4Ig. , 1995, Kidney international.

[22]  J. Allison,et al.  Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. , 1994, Cancer research.

[23]  P. Linsley,et al.  Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. , 1994, Immunity.

[24]  P. Linsley,et al.  Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1 , 1994, The Journal of experimental medicine.

[25]  P. Linsley,et al.  Differential effects of blockade of CD28-B7 on the development of Th1 or Th2 effector cells in experimental leishmaniasis. , 1994, Journal of immunology.

[26]  R. Steinman,et al.  The tissue distribution of the B7-2 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro , 1994, The Journal of experimental medicine.

[27]  P. Linsley,et al.  CTLA4Ig treatment ameliorates the lethality of murine graft-versus-host disease across major histocompatibility complex barriers. , 1994, Transplantation.

[28]  M. Cooke,et al.  Differential up-regulation of the B7-1 and B7-2 costimulatory molecules after Ig receptor engagement by antigen. , 1994, Journal of immunology.

[29]  C. S. Campbell,et al.  REJECTION IN HEART TRANSPLANTATION STRONGLY CORRELATES WITH HLA‐DR ANTIGEN MISMATCH , 1994, Transplantation.

[30]  J. Bluestone,et al.  Absence of B7-dependent responses in CD28-deficient mice. , 1994, Immunity.

[31]  R. Noelle,et al.  The role of CD40 in the regulation of humoral and cell-mediated immunity. , 1994, Immunology today.

[32]  P. Linsley,et al.  Treatment of murine lupus with CTLA4Ig. , 1994, Science.

[33]  P. Linsley,et al.  CTLA-4 can function as a negative regulator of T cell activation. , 1994, Immunity.

[34]  G. Freeman,et al.  A negative regulatory function of B7 revealed in B7-1 transgenic mice. , 1994, Immunity.

[35]  P. Linsley,et al.  Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function , 1994, The Journal of experimental medicine.

[36]  P. Linsley,et al.  CTLA-4 ligands are required to induce an in vivo interleukin 4 response to a gastrointestinal nematode parasite , 1994, The Journal of experimental medicine.

[37]  J. Bluestone,et al.  The B7 and CD28 receptor families. , 1994, Immunology today.

[38]  D. Loh,et al.  Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo. , 1994, Immunity.

[39]  Lieping Chen,et al.  Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. , 1994, Journal of immunology.

[40]  P. Linsley,et al.  Transplantation tolerance induced by CTLA4-Ig. , 1994, Transplantation.

[41]  P. Linsley,et al.  In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice. , 1994, Blood.

[42]  H. Ochs,et al.  Costimulation through CD28 enhances T cell-dependent B cell activation via CD40-CD40L interaction. , 1994, Journal of immunology.

[43]  J. Bluestone,et al.  IL-4 treatment of small splenic B cells induces costimulatory molecules B7-1 and B7-2. , 1994, Journal of immunology.

[44]  P. Linsley,et al.  Effect of CTLA‐4 chimeric protein on rat autoimmune anti‐glomerular basement membrane glomerulonephritis , 1994, European journal of immunology.

[45]  P. Linsley,et al.  Costimulator B7-1 confers antigen-presenting-cell function to parenchymal tissue and in conjunction with tumor necrosis factor alpha leads to autoimmunity in transgenic mice. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[46]  L. Shen,et al.  Molecular cloning and expression of early T cell costimulatory molecule-1 and its characterization as B7-2 molecule. , 1994, Journal of immunology.

[47]  N. Nabavi,et al.  In vitro induction of T cell anergy by blocking B7 and early T cell costimulatory molecule ETC-1/B7-2. , 1994, Immunity.

[48]  R. Flavell,et al.  The role of the T cell costimulator B7-1 in autoimmunity and the induction and maintenance of tolerance to peripheral antigen. , 1994, Immunity.

[49]  M P Cooke,et al.  Resting and anergic B cells are defective in CD28-dependent costimulation of naive CD4+ T cells , 1994, The Journal of experimental medicine.

[50]  D. Harlan,et al.  Mice expressing both B7-1 and viral glycoprotein on pancreatic beta cells along with glycoprotein-specific transgenic T cells develop diabetes due to a breakdown of T-lymphocyte unresponsiveness. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[51]  M. Goldman,et al.  Interleukin‐10 inhibits B7 and intercellular adhesion molecule‐1 expression on human monocytes , 1994, European journal of immunology.

[52]  Y. Wu,et al.  T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells , 1994, The Journal of experimental medicine.

[53]  P. Linsley,et al.  Costimulation of T lymphocytes with integrin ligands intercellular adhesion molecule-1 or vascular cell adhesion molecule-1 induces functional expression of CTLA-4, a second receptor for B7. , 1994, Journal of immunology.

[54]  G. Powers,et al.  Monoclonal antibody 2D10 recognizes a novel T cell costimulatory molecule on activated murine B lymphocytes. , 1994, Journal of immunology.

[55]  B. Hausmann,et al.  Mice transgenic for a soluble form of murine CTLA-4 show enhanced expansion of antigen-specific CD4+ T cells and defective antibody production in vivo , 1994, The Journal of experimental medicine.

[56]  P. Lane,et al.  B cell function in mice transgenic for mCTLA4-H gamma 1: lack of germinal centers correlated with poor affinity maturation and class switching despite normal priming of CD4+ T cells , 1994, The Journal of experimental medicine.

[57]  J. Johnston,et al.  Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity , 1994, The Journal of experimental medicine.

[58]  P. Linsley,et al.  CD28-mediated costimulation of interleukin 2 (IL-2) production plays a critical role in T cell priming for IL-4 and interferon gamma production , 1994, The Journal of experimental medicine.

[59]  J. Ceuppens,et al.  Ligation of B7 with CD28/CTLA‐4 on T cells results in CD40 ligand expression, interleukin‐4 secretion and efficient help for antibody production by B cells , 1993, European journal of immunology.

[60]  J. Bluestone,et al.  Expression and functional significance of an additional ligand for CTLA-4. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[61]  H. Reiser,et al.  Evidence for an additional ligand, distinct from B7, for the CTLA-4 receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[62]  J. Gribben,et al.  Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production , 1993, The Journal of experimental medicine.

[63]  G. Freeman,et al.  Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice. , 1993, Science.

[64]  J. Gribben,et al.  Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. , 1993, Science.

[65]  P. Linsley,et al.  Identification of an alternative CTLA-4 ligand costimulatory for T cell activation. , 1993, Science.

[66]  L. Lanier,et al.  B70 antigen is a second ligand for CTLA-4 and CD28 , 1993, Nature.

[67]  P. Linsley,et al.  Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion , 1993, The Journal of experimental medicine.

[68]  Y. Wu,et al.  A major costimulatory molecule on antigen-presenting cells, CTLA4 ligand A, is distinct from B7 , 1993, The Journal of experimental medicine.

[69]  J. Mcarthur,et al.  CD28-induced costimulation of T helper type 2 cells mediated by induction of responsiveness to interleukin 4 , 1993, The Journal of experimental medicine.

[70]  G. Freeman,et al.  Characterization of CTLA-4 structure and expression on human T cells. , 1993, Journal of immunology.

[71]  V. Stewart,et al.  Disappearance of the lymphoid system in Bcl-2 homozygous mutant chimeric mice. , 1993, Science.

[72]  C. Thompson,et al.  bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death , 1993, Cell.

[73]  P. Linsley,et al.  IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. , 1993, Journal of immunology.

[74]  K P Lee,et al.  Differential T cell costimulatory requirements in CD28-deficient mice. , 1993, Science.

[75]  G. Freeman,et al.  Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[76]  K. Lafferty,et al.  The maintenance of self‐tolerance , 1993, Immunology and cell biology.

[77]  P. Linsley,et al.  CD28 engagement by B7/BB-1 induces transient down-regulation of CD28 synthesis and prolonged unresponsiveness to CD28 signaling. , 1993, Journal of immunology.

[78]  T. Kipps,et al.  Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal , 1993, The Journal of experimental medicine.

[79]  P. Linsley,et al.  Induction of costimulatory molecule B7 in M12 B lymphomas by cAMP or MHC-restricted T cell interaction. , 1993, Journal of immunology.

[80]  P. Linsley,et al.  Expression and function of B7 on human epidermal Langerhans cells. , 1993, Journal of immunology.

[81]  J. Allison,et al.  Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. , 1993, Science.

[82]  C Anasetti,et al.  Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1 , 1993, The Journal of experimental medicine.

[83]  P. Linsley,et al.  The role of the CD28 receptor during T cell responses to antigen. , 1993, Annual review of immunology.

[84]  P. Linsley,et al.  Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4 , 1992, Cell.

[85]  G. Freeman,et al.  CTLA-4 and CD28 mRNA are coexpressed in most T cells after activation. Expression of CTLA-4 and CD28 mRNA does not correlate with the pattern of lymphokine production. , 1992, Journal of immunology.

[86]  P. Linsley,et al.  Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes , 1992, The Journal of experimental medicine.

[87]  G. Freeman,et al.  Signalling through the MHC class II cytoplasmic domain is required for antigen presentation and induces B7 expression , 1992, Nature.

[88]  P. Linsley,et al.  T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[89]  P. Linsley,et al.  Functional expression of the costimulatory molecule, B7/BB1, on murine dendritic cell populations , 1992, The Journal of experimental medicine.

[90]  P. Linsley,et al.  Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. , 1992, Science.

[91]  P. Linsley,et al.  Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. , 1992, Science.

[92]  J. Allison,et al.  Identification and distribution of the costimulatory receptor CD28 in the mouse. , 1992, Journal of immunology.

[93]  P. Linsley,et al.  Costimulation of T-cell growth. , 1992, Current opinion in immunology.

[94]  C. van Kooten,et al.  Interleukin (IL)‐4 production by human T cells: differential regulation of IL‐4 vs. IL‐2 production , 1992, European journal of immunology.

[95]  J. Allison,et al.  CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones , 1992, Nature.

[96]  L. Lanier,et al.  CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes , 1992, The Journal of experimental medicine.

[97]  G. Freeman,et al.  Selective induction of B7/BB-1 on interferon-gamma stimulated monocytes: a potential mechanism for amplification of T cell activation through the CD28 pathway. , 1991, Cellular immunology.

[98]  J. Gribben,et al.  Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7 , 1991, The Journal of experimental medicine.

[99]  M. Mattei,et al.  CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location. , 1991, Journal of immunology.

[100]  J. Gribben,et al.  B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[101]  J. Banchereau,et al.  IL-4 and IL-2 upregulate the expression of antigen B7, the B cell counterstructure to T cell CD28: an amplification mechanism for T-B cell interactions. , 1991, International immunology.

[102]  P. Linsley,et al.  Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation , 1991, The Journal of experimental medicine.

[103]  R. Schreiber,et al.  Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death , 1990, Nature.

[104]  P. Linsley,et al.  T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[105]  J. Allison,et al.  The murine homologue of the T lymphocyte antigen CD28. Molecular cloning and cell surface expression. , 1990, Journal of immunology.

[106]  C. Thompson,et al.  CD28 is an inducible T cell surface antigen that transduces a proliferative signal in CD3+ mature thymocytes. , 1990, Journal of immunology.

[107]  P. Linsley,et al.  Role of the CD28 receptor in T-cell activation. , 1990, Immunology today.

[108]  G. Freeman,et al.  B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. , 1989, Journal of immunology.

[109]  C. Thompson,et al.  CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[110]  F. Denizot,et al.  A new member of the immunoglobulin superfamily—CTLA-4 , 1987, Nature.

[111]  W. Lesslauer,et al.  Biochemical characterization of the 9.3 antigens of human T-cells: simultaneous expression of disulfide-bonded 90-kilodalton dimers and free subunits at the cell surface. , 1986, Molecular immunology.

[112]  T. Yokochi,et al.  B lymphoblast antigen (BB-1) expressed on Epstein-Barr virus-activated B cell blasts, B lymphoblastoid cell lines, and Burkitt's lymphomas. , 1982, Journal of immunology.

[113]  Melvin Cohn,et al.  A Theory of Self-Nonself Discrimination , 1970, Science.